Ferring Pharmaceuticals announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Rekovelle (follitropin delta), recommending that the European Commission grants marketing authorisation for use in controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART), such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle. The European Commission has authority to grant marketing authorisation for medicines in the 28 countries of the European Union (EU). Following a European Commission decision, authorisation can also be granted by national authorities in Norway and Iceland.
If approved, Rekovelle would be administered using an individualised dosing regimen according to a woman’s serum anti-Müllerian hormone (AMH) level and her body weight. AMH is a biomarker used to assess ovarian reserve. This can help to predict ovarian response to controlled ovarian stimulation and thus identify patients who may be at higher risk of experiencing reduced efficacy or increased safety concerns. The individualised dosing regimen determines a specific daily dose of Rekovelle for each patient, with the aim of maintaining efficacy and improving safety during controlled ovarian stimulation. AMH would be measured by a companion diagnostic, the Elecsys AMH Plus immunoassay from F. Hoffmann-La Roche Ltd (Roche).
“The individualised dosing regimen for Rekovelle aims to further enrich the personalised care that fertility specialists offer their patients,” said Dr Per Falk, M.D. Ph.D., chief scientific officer and executive vice president at Ferring Pharmaceuticals. “If approved, this would be the first pairing of a drug with a companion diagnostic for individualised dosing in reproductive medicine.”
The CHMP positive opinion is based on a comprehensive clinical development programme, including the phase 3 ESTHER trials (Evidence-based Stimulation Trial with Human recombinant FSH in Europe and Rest of World), involving 1,326 patients in 11 countries, and over 2,000 cycles of controlled ovarian stimulation.
Non-inferiority was demonstrated in a phase 3 trial for the co-primary endpoints of ongoing pregnancy rate and ongoing implantation rate for Rekovelle compared to follitropin alfa (conventional treatment and dosing regimen). Secondary endpoints, including the number of oocytes retrieved and number of blastocysts obtained, were comparable between both groups. The phase 3 clinical trials also demonstrated no increased immunogenicity risk and a good safety profile for Rekovelle with repeated cycles of controlled ovarian stimulation.
Follitropin delta (also known as FE 999049) is the first recombinant follicle stimulating hormone (FSH) derived from a human cell line. It has been developed for individualised dosing based on a woman’s serum anti-Müllerian hormone (AMH) level, as determined by a companion diagnostic, the Elecsys AMH Plus immunoassay from Roche and her body weight. Follitropin delta is structurally and clinically distinct from other existing recombinant FSH treatments.
The ESTHER trials (Evidence-based Stimulation Trial with Human recombinant FSH in Europe and Rest of World) were randomised, assessor-blind, controlled, multicentre phase 3 trials involving fertility clinics in Europe, Canada, Brazil and Russia.
The Elecsys AMH Plus immunoassay from Roche has been shown to provide a precise, reliable and robust measurement of AMH levels. This fully automated Elecsys AMH Plus immunoassay uses the cobas e and Elecsys immunoassay analysers, determines AMH levels in 18 minutes, making it appropriate for routine clinical use. The Elecsys AMH Plus immunoassay is intended to be used for assessment of ovarian reserve, prediction of response to controlled ovarian stimulation (COS) and establishment of the individual daily dose of Ferring follitropin delta in combination with body weight in COS for the development of multiple follicles in women undergoing an assisted reproductive technology program.